Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H JACKSON

Showing results (701-710 of 770) with videos related to

Pageof 77
Sort By:
Mucosal Immunology|January 23, 2023
High-fat diet-induced resistance to helminth infection via alternative induction of type 2 immunityEvelyn Funjika, Stefano A P Colombo, Kelly S Hayes, et al.
The Journal of Animal Ecology|May 28, 2011
Neonatal mortality of elk driven by climate, predator phenology and predator community compositionKathleen A Griffin, Mark Hebblewhite, Hugh S Robinson, et al.
Blood|November 28, 2014
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsCharlotte Pawlyn, Lorenzo Melchor, Alex Murison, et al.
Haematologica|November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Nature Communications|October 6, 2020
Fetal whole heart blood flow imaging using 4D cine MRIThomas A Roberts, Joshua F P van Amerom, Alena Uus, et al.
Blood Cancer Journal|April 1, 2017
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle controlC Pawlyn, M D Bright, A F Buros, et al.
Blood|June 10, 2011
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2022
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular RiskRuth M de Tute, Charlotte Pawlyn, David A Cairns, et al.
The EMBO Journal|July 19, 2017
Type I interferon is required for T helper (Th) 2 induction by dendritic cellsLauren M Webb, Rachel J Lundie, Jessica G Borger, et al.
The Lancet Regional Health. Europe|December 19, 2023
Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohortPeter D Kirwan, Victoria J Hall, Sarah Foulkes, et al.
Pageof 77

Showing results (701-710 of 770) with videos related to

Sort By:
Pageof 77
Mucosal Immunology|January 23, 2023
High-fat diet-induced resistance to helminth infection via alternative induction of type 2 immunityEvelyn Funjika, Stefano A P Colombo, Kelly S Hayes, et al.
The Journal of Animal Ecology|May 28, 2011
Neonatal mortality of elk driven by climate, predator phenology and predator community compositionKathleen A Griffin, Mark Hebblewhite, Hugh S Robinson, et al.
Blood|November 28, 2014
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsCharlotte Pawlyn, Lorenzo Melchor, Alex Murison, et al.
Haematologica|November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Nature Communications|October 6, 2020
Fetal whole heart blood flow imaging using 4D cine MRIThomas A Roberts, Joshua F P van Amerom, Alena Uus, et al.
Blood Cancer Journal|April 1, 2017
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle controlC Pawlyn, M D Bright, A F Buros, et al.
Blood|June 10, 2011
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2022
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular RiskRuth M de Tute, Charlotte Pawlyn, David A Cairns, et al.
The EMBO Journal|July 19, 2017
Type I interferon is required for T helper (Th) 2 induction by dendritic cellsLauren M Webb, Rachel J Lundie, Jessica G Borger, et al.
The Lancet Regional Health. Europe|December 19, 2023
Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohortPeter D Kirwan, Victoria J Hall, Sarah Foulkes, et al.
Pageof 77